| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/30/2011 | US20110162096 Gene Therapy Using Transposon-Based Vectors |
| 06/30/2011 | US20110162095 TNFSF Single Chain Molecules |
| 06/30/2011 | US20110160845 Drug delivery system and method of manufacturing thereof |
| 06/30/2011 | US20110160309 Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators |
| 06/30/2011 | US20110160305 Oral Delivery of Therapeutic Doses of Glutathione |
| 06/30/2011 | US20110160301 Ascorbate, vitamin k3 and hydroxytolans in the treatment of cancer |
| 06/30/2011 | US20110160297 Schweinfurthin analogues |
| 06/30/2011 | US20110160296 Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine |
| 06/30/2011 | US20110160295 Antitumor agent |
| 06/30/2011 | US20110160293 Prmt1 for target genes of cancer therapy and diagnosis |
| 06/30/2011 | US20110160291 Oligonucleotide Compositions and Their Use to Induce Apoptosis |
| 06/30/2011 | US20110160290 Use of extracellular rna to measure disease |
| 06/30/2011 | US20110160288 Oip5 as a target gene for cancer therapy and diagnosis |
| 06/30/2011 | US20110160287 Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof |
| 06/30/2011 | US20110160284 Supercoiled minicircle dna for gene therapy applications |
| 06/30/2011 | US20110160283 Modulation of cd40 expression |
| 06/30/2011 | US20110160282 Nucleic-acid pharmaceutical composition for cancer therapy |
| 06/30/2011 | US20110160281 RNA Interference Mediated Inhibition of Vascular Cell Adhesion Molecule (VCAM) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 06/30/2011 | US20110160280 Cancer-related genes, cdca5, epha7, stk31 and wdhd1 |
| 06/30/2011 | US20110160278 Methods For Selectively Modulating Survivin Apoptosis Pathways |
| 06/30/2011 | US20110160263 Small molecule inhibition of PDZ-domain interaction |
| 06/30/2011 | US20110160259 Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners |
| 06/30/2011 | US20110160256 Inhibitors of akt activity |
| 06/30/2011 | US20110160255 Inhibitors of akt activity |
| 06/30/2011 | US20110160242 Purified Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same |
| 06/30/2011 | US20110160241 New peptidomimetic compounds |
| 06/30/2011 | US20110160240 Polymorphs and salts of a kinase inhibitor |
| 06/30/2011 | US20110160237 Substituted Heterocyclic Compounds |
| 06/30/2011 | US20110160235 Triazolyl tropane derivatives |
| 06/30/2011 | US20110160232 Certain chemical entities and therapeutic uses thereof |
| 06/30/2011 | US20110160228 Dihydro-iso-ca-4 and analogues: potent cytotoxics, inhibitors of tubulin polymerization |
| 06/30/2011 | US20110160226 Substituted Triazolo-Pyrimidine Compounds |
| 06/30/2011 | US20110160221 Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| 06/30/2011 | US20110160216 Thymidylate Synthase Haplotype is Associated with Tumor Recurrence in Stage II and Stage III Colon Cancer Patients |
| 06/30/2011 | US20110160215 Substituted Triazolo-Pyrazine Compounds |
| 06/30/2011 | US20110160209 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
| 06/30/2011 | US20110160207 Heterocyclic amide compounds useful as kinase inhibitors |
| 06/30/2011 | US20110160205 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| 06/30/2011 | US20110160204 PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS |
| 06/30/2011 | US20110160203 Substituted Pyrrolo-Aminopyrimidine Compounds |
| 06/30/2011 | US20110160192 Biaryl amino acids and their use in dna binding oligomers |
| 06/30/2011 | US20110160190 Carboline derivatives useful in the inhibition of angiogenesis |
| 06/30/2011 | US20110160189 Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses |
| 06/30/2011 | US20110160183 Inhibitors of akt activity |
| 06/30/2011 | US20110160181 Substituted pyrazoline compounds, their preparation and use as medicaments |
| 06/30/2011 | US20110160180 Cannabinoid Receptor Ligands |
| 06/30/2011 | US20110160175 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer |
| 06/30/2011 | US20110160170 Compositions and methods of inducing endoplasmic reticulum stress response |
| 06/30/2011 | US20110160169 Method for producing high sapogenin content composition |
| 06/30/2011 | US20110160165 7-Pyrazolyl Tetracycline Compounds and Methods of Use Thereof |
| 06/30/2011 | US20110160163 INHIBITORS OF p38 |
| 06/30/2011 | US20110160160 Methods for heat shock protein dependent cancer treatment |
| 06/30/2011 | US20110160159 Treatment of cancer |
| 06/30/2011 | US20110160152 Extracts of aquilaria hulls and use thereof in the treatment of cancer |
| 06/30/2011 | US20110160151 Novel Acetates of 2-Deoxy Monosaccharides with Anticancer Activity |
| 06/30/2011 | US20110160147 Novel dual targeting antitumoral conjugates |
| 06/30/2011 | US20110160146 Conjungation of Small Molecules to Octaarginine Transporters for Overcoming Multi-Drug Resistance |
| 06/30/2011 | US20110160130 Cancer treatment method |
| 06/30/2011 | US20110160129 Therapeutic Agent Preparations for Delivery Into a Lumen of the Intestinal Tract Using a Swallowable Drug Delivery Device |
| 06/30/2011 | US20110160120 Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
| 06/30/2011 | US20110160119 Anti-inflammatory compounds and uses thereof |
| 06/30/2011 | US20110159532 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF |
| 06/30/2011 | US20110159131 Use of strains of lactobacillus and by-products thereof for inhibiting formation of blood vessels |
| 06/30/2011 | US20110159121 Methods and compositions for identifying, producing and using plant-derived products for modulating cell function and aging |
| 06/30/2011 | US20110159120 Synergistic anti-inflammatory compositions comprising boswellia serrata extracts |
| 06/30/2011 | US20110159116 Biocompatible materials for medical devices |
| 06/30/2011 | US20110159114 Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
| 06/30/2011 | US20110159112 Recombinant alpha-fetoprotein and compositions thereof |
| 06/30/2011 | US20110159111 Pharmaceutical combinations |
| 06/30/2011 | US20110159088 ORAL PHARMACEUTICAL FOR BASED ON AT LEAST ONE ACTIVE PRINCIPLE WHOSE SOLUBILITY VARIES AS A FUNCTION OF THE GASTRIC pH CONDITIONS |
| 06/30/2011 | US20110159085 Abt-263 capsule |
| 06/30/2011 | US20110159080 Composition comprising liposome-entrapped doxorubicin and methods of administration |
| 06/30/2011 | US20110159054 Nanoparticulate bicalutamide formulations |
| 06/30/2011 | US20110159052 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 06/30/2011 | US20110159043 Allogeneic vaccine and methods to synthesize same |
| 06/30/2011 | US20110159034 Methods and reagents for vaccination which generate a cd8 t cell immune response |
| 06/30/2011 | US20110159032 Modified vaccinia virus ankara for the vaccination of neonates |
| 06/30/2011 | US20110159022 Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine |
| 06/30/2011 | US20110159021 Xbp1, cd138, and cs1 peptides |
| 06/30/2011 | US20110159017 Trytophan catabolism in cancer treatment and diagnosis |
| 06/30/2011 | US20110159014 Anti-her2 antibody variants |
| 06/30/2011 | US20110159009 Anti-vegf antibodies |
| 06/30/2011 | US20110159008 Antibodies Binding To The Extracellular Domain Of The Receptor Tyrosine Kinase ALK |
| 06/30/2011 | US20110159003 Ligands That Bind Il-4 and/or Il-13 |
| 06/30/2011 | US20110159000 Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions |
| 06/30/2011 | US20110158999 Antagonists of protease activated receptor-1 (par1) |
| 06/30/2011 | US20110158997 Single chain fragment variable antibody libraries and uses thereof |
| 06/30/2011 | US20110158994 Polypeptides specifically binding to vascular endothelial growth factor receptor-2 and methods therefor |
| 06/30/2011 | US20110158993 Train-R: A Cysteine Rich Member of the TNF-Receptor Family |
| 06/30/2011 | US20110158992 Engineered Anti-IL-23R Antibodies |
| 06/30/2011 | US20110158991 Cytotoxic agents comprising new maytansinoids |
| 06/30/2011 | US20110158990 5-anilinoimidazopyridines and methods of use |
| 06/30/2011 | US20110158989 Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS |
| 06/30/2011 | US20110158988 Antibodies against extracellular domains 2 and 3 or her2 |
| 06/30/2011 | US20110158987 Novel antibody formulation |
| 06/30/2011 | US20110158983 Compositions and methods for mucositis and oncology therapies |
| 06/30/2011 | US20110158975 Use of runx3 and mir-532-5p as cancer markers and therapeutic targets |
| 06/30/2011 | US20110158973 Suppression of cancers |
| 06/30/2011 | US20110158971 Compositions comprising n3 alkylated benzimidazole derivatives as mek inhibitors and methods of use thereof |
| 06/30/2011 | US20110158967 Mesenchymal stem cell and the method of use thereof |